No Data
With 59% Institutional Ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) Is a Favorite Amongst the Big Guns
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
SA Asks: Which Big Pharmas Would Be Most Impacted by Higher Tariffs?
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Express News | Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing
